Physician profile
Alice Babst
NPI 1134162753
$8,082.33
in general payments reported to CMS, 2019-2025
26 companies · $6,638 in 2025
The $6,638 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $89.96 · 2021: $470 · 2022: $51.49 · 2023: $193 · 2024: $301 · 2025: $6,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Travel and Lodging: $1,596 · Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Travel and Lodging | $1,596.27 |
| Food and Beverage | $1,035.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,288.74 | 2025 | |
| Abbvie INC. | $283.38 | 2019-2024 | |
| Hologic Sales and Service, LLC | $246.42 | 2019-2024 | Aptima, Affirm Prone Biopsy System |
| Mayne Pharma Commercial LLC | $219.28 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $124.82 | 2021 | |
| Endo Pharmaceuticals INC. | $109.02 | 2020-2022 | |
| Pfizer INC. | $104.14 | 2019-2024 | |
| Evofem Biosciences, INC. | $83.36 | 2021-2025 | Phexxi, Solosec, Phexx |
| Novo Nordisk INC | $74.04 | 2019-2024 | Wegovy |
| Sage Therapeutics, LLC | $73.06 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $63.00 | 2023-2025 | Myfembree |
| Takeda Pharmaceuticals U.S.A., INC. | $62.63 | 2019-2020 | |
| Millicent US INC | $57.41 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Avion Pharmaceuticals | $41.11 | 2021 | |
| Shield Therapeutics INC | $35.58 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $29.17 | 2019-2023 | Slynd |
| Merck Sharp & Dohme LLC | $27.34 | 2019-2024 | Gardasil, Gardasil 9 |
| Pacira Pharmaceuticals Incorporated | $24.31 | 2025 | Exparel, Iovera |
| Bayer Healthcare Pharmaceuticals INC. | $23.83 | 2025 | |
| Supernus Pharmaceuticals, INC. | $20.80 | 2025 | Qelbree |
| Lilly USA, LLC | $18.71 | 2025 | Zepbound |
| Astellas Pharma US INC | $15.62 | 2024 | Veozah |
| Exact Sciences Corporation | $15.61 | 2025 | The Cologuard Plus Collection Kit |
| Amag Pharmaceuticals, INC. | $15.43 | 2020 | |
| Scynexis, INC. | $14.25 | 2022 | |
| Allergan, INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Babst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.